Bausch Health Companies (BHC) Stock Price, News & Analysis

Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Key Stats

• Today's Range: C$10.09 to C$10.52
• 50-Day Range: C$8.73 to C$11.62
• 52-Week Range: C$5.45 to C$15.43
• Volume: 544,873 shs
• Average Volume: 277,343 shs
• Market Capitalization: C$2.71 billion
• P/E Ratio: N/A
• Dividend Yield: 0.76%
• Price Target: C$9.00
• Consensus Rating: Hold

Bausch Health Companies Stock Analysis - MarketRank™

Bausch Health Companies scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Bausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bausch Health Companies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch Health Companies is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch Health Companies is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Bausch Health Companies has a PEG Ratio of 0.21. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BHC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Bausch Health Companies has a dividend yield of 0.76%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bausch Health Companies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BHC.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.09

News Sentiment

Bausch Health Companies has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Bausch Health Companies this week, compared to 2 articles on an average week.

Search Interest

14 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bausch Health Companies insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.28% of the stock of Bausch Health Companies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.01% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BHC Stock Analysis - Frequently Asked Questions

How have BHC shares performed this year?

Bausch Health Companies' stock was trading at C$11.62 at the start of the year. Since then, BHC stock has decreased by 10.4% and is now trading at C$10.41.
View the best growth stocks for 2025 here.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch Health Companies investors own include Chesapeake Energy (CHKAQ), Meta Platforms (META), Advanced Micro Devices (AMD), Enbridge (ENB), Shopify (SHOP), NVIDIA (NVDA) and Ford Motor (F).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:BHC
• CUSIP: N/A
• CIK: N/A
• Web: www.valeant.com
• Phone: 514-744-6792
• Fax: N/A
• Employees: 19,900
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$9.00
• High Stock Price Target: C$9.00
• Low Stock Price Target: C$9.00
• Potential Upside/Downside: -13.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 1.88
• P/E Growth: 0.21
• Net Income: C$-125,650,969.23
• Net Margins: -1.88%
• Pretax Margin: N/A
• Return on Equity: 15.87%
• Return on Assets: 4.16%

Debt

• Debt-to-Equity Ratio: -1,831.94
• Current Ratio: 1.19
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: C$6.69 billion
• Price / Sales: 0.40
• Cash Flow: C$1.34 per share
• Price / Cash Flow: 7.76
• Book Value: C($0.66) per share
• Price / Book: -15.85

Miscellaneous

• Outstanding Shares: 260,055,152
• Free Float: N/A
• Market Cap: C$2.71 billion
• Optionable: Not Optionable
• Beta: 0.77